JP2009518292A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009518292A5 JP2009518292A5 JP2008542778A JP2008542778A JP2009518292A5 JP 2009518292 A5 JP2009518292 A5 JP 2009518292A5 JP 2008542778 A JP2008542778 A JP 2008542778A JP 2008542778 A JP2008542778 A JP 2008542778A JP 2009518292 A5 JP2009518292 A5 JP 2009518292A5
- Authority
- JP
- Japan
- Prior art keywords
- benzimidazol
- biphenyl
- ethylamine
- ethyl
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 206010047700 Vomiting Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 230000008673 vomiting Effects 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 150000001204 N-oxides Chemical class 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- -1 methylenedioxy, ethylenedioxy Chemical group 0.000 claims 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 208000008811 Agoraphobia Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- CJKRCJXOIXCMQV-OAHLLOKOSA-N (1r)-1-[1-(3-phenylphenyl)benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC([C@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1 CJKRCJXOIXCMQV-OAHLLOKOSA-N 0.000 claims 1
- ZKJDXSBGJFPJLC-CQSZACIVSA-N (1r)-1-[1-[3-(1,3-benzodioxol-4-yl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC([C@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC2=C1OCO2 ZKJDXSBGJFPJLC-CQSZACIVSA-N 0.000 claims 1
- TUYYWNHWWSDRIQ-CYBMUJFWSA-N (1r)-1-[1-[3-(2,3-difluoro-6-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC=C(F)C(F)=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@@H](C)N)=C1 TUYYWNHWWSDRIQ-CYBMUJFWSA-N 0.000 claims 1
- YOSFSEAGAQAXBO-OAHLLOKOSA-N (1r)-1-[1-[3-(2,3-dimethoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC=CC(C=2C=C(C=CC=2)N2C3=CC=C(C=C3N=C2)[C@@H](C)N)=C1OC YOSFSEAGAQAXBO-OAHLLOKOSA-N 0.000 claims 1
- WPOMEYIQKVWZFV-OAHLLOKOSA-N (1r)-1-[1-[3-(2,4-dimethoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC(OC)=CC=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@@H](C)N)=C1 WPOMEYIQKVWZFV-OAHLLOKOSA-N 0.000 claims 1
- MZWSTKBMZXQVOO-CYBMUJFWSA-N (1r)-1-[1-[3-(2,6-dichlorophenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC([C@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=C(Cl)C=CC=C1Cl MZWSTKBMZXQVOO-CYBMUJFWSA-N 0.000 claims 1
- GLCNXFUJTTUNSL-CYBMUJFWSA-N (1r)-1-[1-[3-(2,6-difluorophenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC([C@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=C(F)C=CC=C1F GLCNXFUJTTUNSL-CYBMUJFWSA-N 0.000 claims 1
- DZOIOTNHUXUDGQ-OAHLLOKOSA-N (1r)-1-[1-[3-(2,6-dimethoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@@H](C)N)=C1 DZOIOTNHUXUDGQ-OAHLLOKOSA-N 0.000 claims 1
- NPPYMOZIWZOUSL-CQSZACIVSA-N (1r)-1-[1-[3-(2-chloro-6-fluoro-3-methylphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC([C@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=C(F)C=CC(C)=C1Cl NPPYMOZIWZOUSL-CQSZACIVSA-N 0.000 claims 1
- KWLIBQUJFONRSM-CQSZACIVSA-N (1r)-1-[1-[3-(2-chloro-6-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC=CC(Cl)=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@@H](C)N)=C1 KWLIBQUJFONRSM-CQSZACIVSA-N 0.000 claims 1
- FGERINFNQINSMH-CQSZACIVSA-N (1r)-1-[1-[3-(2-fluoro-6-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC=CC(F)=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@@H](C)N)=C1 FGERINFNQINSMH-CQSZACIVSA-N 0.000 claims 1
- VPHQMUURAIOPTJ-OAHLLOKOSA-N (1r)-1-[1-[3-(2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC=CC=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@@H](C)N)=C1 VPHQMUURAIOPTJ-OAHLLOKOSA-N 0.000 claims 1
- WXYBWPPRLHMCCR-GOSISDBHSA-N (1r)-1-[1-[3-(2-piperazin-1-ylphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC([C@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1N1CCNCC1 WXYBWPPRLHMCCR-GOSISDBHSA-N 0.000 claims 1
- DWWPQNSBCRBVNY-CYBMUJFWSA-N (1r)-1-[1-[3-(3,5-difluoro-2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=C(F)C=C(F)C=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@@H](C)N)=C1 DWWPQNSBCRBVNY-CYBMUJFWSA-N 0.000 claims 1
- QDLHGPWPNGLLCA-CQSZACIVSA-N (1r)-1-[1-[3-(3-chloro-2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=C(Cl)C=CC=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@@H](C)N)=C1 QDLHGPWPNGLLCA-CQSZACIVSA-N 0.000 claims 1
- LQAWDGAFBLVCGO-CQSZACIVSA-N (1r)-1-[1-[3-(3-fluoro-2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=C(F)C=CC=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@@H](C)N)=C1 LQAWDGAFBLVCGO-CQSZACIVSA-N 0.000 claims 1
- ROUPFXQEQBKISE-CQSZACIVSA-N (1r)-1-[1-[3-(4-fluoro-2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC(F)=CC=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@@H](C)N)=C1 ROUPFXQEQBKISE-CQSZACIVSA-N 0.000 claims 1
- OGQNTQKGAMZNDT-CQSZACIVSA-N (1r)-1-[1-[3-(5-chloro-2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC=C(Cl)C=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@@H](C)N)=C1 OGQNTQKGAMZNDT-CQSZACIVSA-N 0.000 claims 1
- DOHDMDZZTAULIV-CQSZACIVSA-N (1r)-1-[1-[3-(5-fluoro-2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC=C(F)C=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@@H](C)N)=C1 DOHDMDZZTAULIV-CQSZACIVSA-N 0.000 claims 1
- VIROKERMYCAYND-CQSZACIVSA-N (1r)-1-[1-[3-(6-chloro-2-fluoro-3-methylphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC([C@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=C(Cl)C=CC(C)=C1F VIROKERMYCAYND-CQSZACIVSA-N 0.000 claims 1
- VOXSQTUIFNZBGV-LJQANCHMSA-N (1r)-1-[1-[3-[2-(morpholin-4-ylmethyl)phenyl]phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC([C@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1CN1CCOCC1 VOXSQTUIFNZBGV-LJQANCHMSA-N 0.000 claims 1
- AUGQXCMJYAPTJI-CQSZACIVSA-N (1r)-1-[1-[3-[2-(trifluoromethoxy)phenyl]phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC([C@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1OC(F)(F)F AUGQXCMJYAPTJI-CQSZACIVSA-N 0.000 claims 1
- CJKRCJXOIXCMQV-HNNXBMFYSA-N (1s)-1-[1-(3-phenylphenyl)benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC([C@@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1 CJKRCJXOIXCMQV-HNNXBMFYSA-N 0.000 claims 1
- ZKJDXSBGJFPJLC-AWEZNQCLSA-N (1s)-1-[1-[3-(1,3-benzodioxol-4-yl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC([C@@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC2=C1OCO2 ZKJDXSBGJFPJLC-AWEZNQCLSA-N 0.000 claims 1
- TUYYWNHWWSDRIQ-ZDUSSCGKSA-N (1s)-1-[1-[3-(2,3-difluoro-6-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC=C(F)C(F)=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@H](C)N)=C1 TUYYWNHWWSDRIQ-ZDUSSCGKSA-N 0.000 claims 1
- YOSFSEAGAQAXBO-HNNXBMFYSA-N (1s)-1-[1-[3-(2,3-dimethoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC=CC(C=2C=C(C=CC=2)N2C3=CC=C(C=C3N=C2)[C@H](C)N)=C1OC YOSFSEAGAQAXBO-HNNXBMFYSA-N 0.000 claims 1
- WPOMEYIQKVWZFV-HNNXBMFYSA-N (1s)-1-[1-[3-(2,4-dimethoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC(OC)=CC=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@H](C)N)=C1 WPOMEYIQKVWZFV-HNNXBMFYSA-N 0.000 claims 1
- MZWSTKBMZXQVOO-ZDUSSCGKSA-N (1s)-1-[1-[3-(2,6-dichlorophenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC([C@@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=C(Cl)C=CC=C1Cl MZWSTKBMZXQVOO-ZDUSSCGKSA-N 0.000 claims 1
- GLCNXFUJTTUNSL-ZDUSSCGKSA-N (1s)-1-[1-[3-(2,6-difluorophenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC([C@@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=C(F)C=CC=C1F GLCNXFUJTTUNSL-ZDUSSCGKSA-N 0.000 claims 1
- DZOIOTNHUXUDGQ-HNNXBMFYSA-N (1s)-1-[1-[3-(2,6-dimethoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@H](C)N)=C1 DZOIOTNHUXUDGQ-HNNXBMFYSA-N 0.000 claims 1
- NPPYMOZIWZOUSL-AWEZNQCLSA-N (1s)-1-[1-[3-(2-chloro-6-fluoro-3-methylphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC([C@@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=C(F)C=CC(C)=C1Cl NPPYMOZIWZOUSL-AWEZNQCLSA-N 0.000 claims 1
- KWLIBQUJFONRSM-AWEZNQCLSA-N (1s)-1-[1-[3-(2-chloro-6-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC=CC(Cl)=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@H](C)N)=C1 KWLIBQUJFONRSM-AWEZNQCLSA-N 0.000 claims 1
- FGERINFNQINSMH-AWEZNQCLSA-N (1s)-1-[1-[3-(2-fluoro-6-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC=CC(F)=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@H](C)N)=C1 FGERINFNQINSMH-AWEZNQCLSA-N 0.000 claims 1
- VPHQMUURAIOPTJ-HNNXBMFYSA-N (1s)-1-[1-[3-(2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC=CC=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@H](C)N)=C1 VPHQMUURAIOPTJ-HNNXBMFYSA-N 0.000 claims 1
- WXYBWPPRLHMCCR-SFHVURJKSA-N (1s)-1-[1-[3-(2-piperazin-1-ylphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC([C@@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1N1CCNCC1 WXYBWPPRLHMCCR-SFHVURJKSA-N 0.000 claims 1
- DWWPQNSBCRBVNY-ZDUSSCGKSA-N (1s)-1-[1-[3-(3,5-difluoro-2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=C(F)C=C(F)C=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@H](C)N)=C1 DWWPQNSBCRBVNY-ZDUSSCGKSA-N 0.000 claims 1
- OJWJWXOLHNSREK-LBPRGKRZSA-N (1s)-1-[1-[3-(3-chloro-2,6-difluorophenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC([C@@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=C(F)C=CC(Cl)=C1F OJWJWXOLHNSREK-LBPRGKRZSA-N 0.000 claims 1
- LQAWDGAFBLVCGO-AWEZNQCLSA-N (1s)-1-[1-[3-(3-fluoro-2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=C(F)C=CC=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@H](C)N)=C1 LQAWDGAFBLVCGO-AWEZNQCLSA-N 0.000 claims 1
- ROUPFXQEQBKISE-AWEZNQCLSA-N (1s)-1-[1-[3-(4-fluoro-2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC(F)=CC=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@H](C)N)=C1 ROUPFXQEQBKISE-AWEZNQCLSA-N 0.000 claims 1
- DOHDMDZZTAULIV-AWEZNQCLSA-N (1s)-1-[1-[3-(5-fluoro-2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC=C(F)C=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@H](C)N)=C1 DOHDMDZZTAULIV-AWEZNQCLSA-N 0.000 claims 1
- VIROKERMYCAYND-AWEZNQCLSA-N (1s)-1-[1-[3-(6-chloro-2-fluoro-3-methylphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC([C@@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=C(Cl)C=CC(C)=C1F VIROKERMYCAYND-AWEZNQCLSA-N 0.000 claims 1
- VOXSQTUIFNZBGV-IBGZPJMESA-N (1s)-1-[1-[3-[2-(morpholin-4-ylmethyl)phenyl]phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC([C@@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1CN1CCOCC1 VOXSQTUIFNZBGV-IBGZPJMESA-N 0.000 claims 1
- AUGQXCMJYAPTJI-AWEZNQCLSA-N (1s)-1-[1-[3-[2-(trifluoromethoxy)phenyl]phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC([C@@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1OC(F)(F)F AUGQXCMJYAPTJI-AWEZNQCLSA-N 0.000 claims 1
- CJKRCJXOIXCMQV-UHFFFAOYSA-N 1-[1-(3-phenylphenyl)benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC(C(N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1 CJKRCJXOIXCMQV-UHFFFAOYSA-N 0.000 claims 1
- KXHCDIDNBFAURY-UHFFFAOYSA-N 1-[1-[3-(2-fluorophenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC(C(N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1F KXHCDIDNBFAURY-UHFFFAOYSA-N 0.000 claims 1
- VPHQMUURAIOPTJ-UHFFFAOYSA-N 1-[1-[3-(2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC=CC=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)C(C)N)=C1 VPHQMUURAIOPTJ-UHFFFAOYSA-N 0.000 claims 1
- XQLLHVNGGCGWOW-UHFFFAOYSA-N 1-[1-[3-(4-fluorophenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC(C(N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=C(F)C=C1 XQLLHVNGGCGWOW-UHFFFAOYSA-N 0.000 claims 1
- DOHDMDZZTAULIV-UHFFFAOYSA-N 1-[1-[3-(5-fluoro-2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=CC=C(F)C=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)C(C)N)=C1 DOHDMDZZTAULIV-UHFFFAOYSA-N 0.000 claims 1
- AUGQXCMJYAPTJI-UHFFFAOYSA-N 1-[1-[3-[2-(trifluoromethoxy)phenyl]phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC(C(N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1OC(F)(F)F AUGQXCMJYAPTJI-UHFFFAOYSA-N 0.000 claims 1
- RFGVTOIEYHCKAL-OAHLLOKOSA-N 1-[2-[3-[5-[(1r)-1-aminoethyl]benzimidazol-1-yl]phenyl]phenyl]ethanone Chemical compound C1=NC2=CC([C@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1C(C)=O RFGVTOIEYHCKAL-OAHLLOKOSA-N 0.000 claims 1
- RFGVTOIEYHCKAL-HNNXBMFYSA-N 1-[2-[3-[5-[(1s)-1-aminoethyl]benzimidazol-1-yl]phenyl]phenyl]ethanone Chemical compound C1=NC2=CC([C@@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1C(C)=O RFGVTOIEYHCKAL-HNNXBMFYSA-N 0.000 claims 1
- BNSRXWGMIKNAGW-UHFFFAOYSA-N 2-[3-[5-(1-aminoethyl)benzimidazol-1-yl]phenyl]benzonitrile Chemical compound C1=NC2=CC(C(N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1C#N BNSRXWGMIKNAGW-UHFFFAOYSA-N 0.000 claims 1
- YHDJWQUVASWUST-CQSZACIVSA-N 2-[3-[5-[(1r)-1-aminoethyl]benzimidazol-1-yl]phenyl]-5-(trifluoromethyl)benzonitrile Chemical compound C1=NC2=CC([C@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=C(C(F)(F)F)C=C1C#N YHDJWQUVASWUST-CQSZACIVSA-N 0.000 claims 1
- ZKAHUZIAOGHZPV-CQSZACIVSA-N 2-[3-[5-[(1r)-1-aminoethyl]benzimidazol-1-yl]phenyl]-5-fluorobenzonitrile Chemical compound C1=NC2=CC([C@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=C(F)C=C1C#N ZKAHUZIAOGHZPV-CQSZACIVSA-N 0.000 claims 1
- QRXIIUKOQPUXMZ-CYBMUJFWSA-N 2-[3-[5-[(1r)-1-aminoethyl]benzimidazol-1-yl]phenyl]-6-chlorophenol Chemical compound C1=NC2=CC([C@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC(Cl)=C1O QRXIIUKOQPUXMZ-CYBMUJFWSA-N 0.000 claims 1
- VEIGGNXYRIZKRE-CQSZACIVSA-N 2-[3-[5-[(1r)-1-aminoethyl]benzimidazol-1-yl]phenyl]-6-fluorobenzonitrile Chemical compound C1=NC2=CC([C@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC(F)=C1C#N VEIGGNXYRIZKRE-CQSZACIVSA-N 0.000 claims 1
- MBOOMVFLCVGQQA-CQSZACIVSA-N 2-[3-[5-[(1r)-1-aminoethyl]benzimidazol-1-yl]phenyl]benzamide Chemical compound C1=NC2=CC([C@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1C(N)=O MBOOMVFLCVGQQA-CQSZACIVSA-N 0.000 claims 1
- BNSRXWGMIKNAGW-OAHLLOKOSA-N 2-[3-[5-[(1r)-1-aminoethyl]benzimidazol-1-yl]phenyl]benzonitrile Chemical compound C1=NC2=CC([C@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1C#N BNSRXWGMIKNAGW-OAHLLOKOSA-N 0.000 claims 1
- YHDJWQUVASWUST-AWEZNQCLSA-N 2-[3-[5-[(1s)-1-aminoethyl]benzimidazol-1-yl]phenyl]-5-(trifluoromethyl)benzonitrile Chemical compound C1=NC2=CC([C@@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=C(C(F)(F)F)C=C1C#N YHDJWQUVASWUST-AWEZNQCLSA-N 0.000 claims 1
- ZKAHUZIAOGHZPV-AWEZNQCLSA-N 2-[3-[5-[(1s)-1-aminoethyl]benzimidazol-1-yl]phenyl]-5-fluorobenzonitrile Chemical compound C1=NC2=CC([C@@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=C(F)C=C1C#N ZKAHUZIAOGHZPV-AWEZNQCLSA-N 0.000 claims 1
- QRXIIUKOQPUXMZ-ZDUSSCGKSA-N 2-[3-[5-[(1s)-1-aminoethyl]benzimidazol-1-yl]phenyl]-6-chlorophenol Chemical compound C1=NC2=CC([C@@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC(Cl)=C1O QRXIIUKOQPUXMZ-ZDUSSCGKSA-N 0.000 claims 1
- VEIGGNXYRIZKRE-AWEZNQCLSA-N 2-[3-[5-[(1s)-1-aminoethyl]benzimidazol-1-yl]phenyl]-6-fluorobenzonitrile Chemical compound C1=NC2=CC([C@@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC(F)=C1C#N VEIGGNXYRIZKRE-AWEZNQCLSA-N 0.000 claims 1
- MBOOMVFLCVGQQA-AWEZNQCLSA-N 2-[3-[5-[(1s)-1-aminoethyl]benzimidazol-1-yl]phenyl]benzamide Chemical compound C1=NC2=CC([C@@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1C(N)=O MBOOMVFLCVGQQA-AWEZNQCLSA-N 0.000 claims 1
- BNSRXWGMIKNAGW-HNNXBMFYSA-N 2-[3-[5-[(1s)-1-aminoethyl]benzimidazol-1-yl]phenyl]benzonitrile Chemical compound C1=NC2=CC([C@@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1C#N BNSRXWGMIKNAGW-HNNXBMFYSA-N 0.000 claims 1
- OHHDGSBAERYHES-CQSZACIVSA-N 3-[3-[5-[(1r)-1-aminoethyl]benzimidazol-1-yl]phenyl]-4-chlorobenzonitrile Chemical compound C1=NC2=CC([C@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC(C#N)=CC=C1Cl OHHDGSBAERYHES-CQSZACIVSA-N 0.000 claims 1
- OHHDGSBAERYHES-AWEZNQCLSA-N 3-[3-[5-[(1s)-1-aminoethyl]benzimidazol-1-yl]phenyl]-4-chlorobenzonitrile Chemical compound C1=NC2=CC([C@@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC(C#N)=CC=C1Cl OHHDGSBAERYHES-AWEZNQCLSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 208000017164 Chronobiology disease Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000002091 Febrile Seizures Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 206010029333 Neurosis Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 206010033892 Paraplegia Diseases 0.000 claims 1
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010066962 Procedural nausea Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000013200 Stress disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 208000029650 alcohol withdrawal Diseases 0.000 claims 1
- 125000004702 alkoxy alkyl carbonyl group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 201000002426 animal phobia Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 206010025482 malaise Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- AGKXNDOYPQMADM-MRXNPFEDSA-N n-[(1r)-1-[1-(3-phenylphenyl)benzimidazol-5-yl]ethyl]acetamide Chemical compound C1=NC2=CC([C@H](NC(C)=O)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1 AGKXNDOYPQMADM-MRXNPFEDSA-N 0.000 claims 1
- AWVYIUGTVFUVFQ-OAHLLOKOSA-N n-[(1r)-1-[1-[3-(1,3-benzodioxol-4-yl)phenyl]benzimidazol-5-yl]ethyl]acetamide Chemical compound C1=NC2=CC([C@H](NC(C)=O)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC2=C1OCO2 AWVYIUGTVFUVFQ-OAHLLOKOSA-N 0.000 claims 1
- UYLLMTPLYNFJAL-MRXNPFEDSA-N n-[(1r)-1-[1-[3-(2-acetylphenyl)phenyl]benzimidazol-5-yl]ethyl]acetamide Chemical compound C1=NC2=CC([C@H](NC(C)=O)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1C(C)=O UYLLMTPLYNFJAL-MRXNPFEDSA-N 0.000 claims 1
- FRMLZTKAEAXIRP-OAHLLOKOSA-N n-[(1r)-1-[1-[3-(2-cyano-4-fluorophenyl)phenyl]benzimidazol-5-yl]ethyl]acetamide Chemical compound C1=NC2=CC([C@H](NC(C)=O)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=C(F)C=C1C#N FRMLZTKAEAXIRP-OAHLLOKOSA-N 0.000 claims 1
- IWWSRBSXDQQAGW-MRXNPFEDSA-N n-[(1r)-1-[1-[3-(2-cyanophenyl)phenyl]benzimidazol-5-yl]ethyl]acetamide Chemical compound C1=NC2=CC([C@H](NC(C)=O)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1C#N IWWSRBSXDQQAGW-MRXNPFEDSA-N 0.000 claims 1
- SUONAIKREXBHLR-MRXNPFEDSA-N n-[(1r)-1-[1-[3-(2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethyl]acetamide Chemical compound COC1=CC=CC=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@@H](C)NC(C)=O)=C1 SUONAIKREXBHLR-MRXNPFEDSA-N 0.000 claims 1
- ZFDLVBOYJCBUAR-OAHLLOKOSA-N n-[(1r)-1-[1-[3-(5-chloro-2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethyl]acetamide Chemical compound COC1=CC=C(Cl)C=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@@H](C)NC(C)=O)=C1 ZFDLVBOYJCBUAR-OAHLLOKOSA-N 0.000 claims 1
- DTELSNVHSFXARH-MRXNPFEDSA-N n-[(1r)-1-[1-[3-[2-(methanesulfonamido)phenyl]phenyl]benzimidazol-5-yl]ethyl]acetamide Chemical compound C1=NC2=CC([C@H](NC(C)=O)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1NS(C)(=O)=O DTELSNVHSFXARH-MRXNPFEDSA-N 0.000 claims 1
- AGKXNDOYPQMADM-INIZCTEOSA-N n-[(1s)-1-[1-(3-phenylphenyl)benzimidazol-5-yl]ethyl]acetamide Chemical compound C1=NC2=CC([C@@H](NC(C)=O)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1 AGKXNDOYPQMADM-INIZCTEOSA-N 0.000 claims 1
- AWVYIUGTVFUVFQ-HNNXBMFYSA-N n-[(1s)-1-[1-[3-(1,3-benzodioxol-4-yl)phenyl]benzimidazol-5-yl]ethyl]acetamide Chemical compound C1=NC2=CC([C@@H](NC(C)=O)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC2=C1OCO2 AWVYIUGTVFUVFQ-HNNXBMFYSA-N 0.000 claims 1
- UYLLMTPLYNFJAL-INIZCTEOSA-N n-[(1s)-1-[1-[3-(2-acetylphenyl)phenyl]benzimidazol-5-yl]ethyl]acetamide Chemical compound C1=NC2=CC([C@@H](NC(C)=O)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1C(C)=O UYLLMTPLYNFJAL-INIZCTEOSA-N 0.000 claims 1
- FRMLZTKAEAXIRP-HNNXBMFYSA-N n-[(1s)-1-[1-[3-(2-cyano-4-fluorophenyl)phenyl]benzimidazol-5-yl]ethyl]acetamide Chemical compound C1=NC2=CC([C@@H](NC(C)=O)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=C(F)C=C1C#N FRMLZTKAEAXIRP-HNNXBMFYSA-N 0.000 claims 1
- IWWSRBSXDQQAGW-INIZCTEOSA-N n-[(1s)-1-[1-[3-(2-cyanophenyl)phenyl]benzimidazol-5-yl]ethyl]acetamide Chemical compound C1=NC2=CC([C@@H](NC(C)=O)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1C#N IWWSRBSXDQQAGW-INIZCTEOSA-N 0.000 claims 1
- SUONAIKREXBHLR-INIZCTEOSA-N n-[(1s)-1-[1-[3-(2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethyl]acetamide Chemical compound COC1=CC=CC=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@H](C)NC(C)=O)=C1 SUONAIKREXBHLR-INIZCTEOSA-N 0.000 claims 1
- ZFDLVBOYJCBUAR-HNNXBMFYSA-N n-[(1s)-1-[1-[3-(5-chloro-2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethyl]acetamide Chemical compound COC1=CC=C(Cl)C=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)[C@H](C)NC(C)=O)=C1 ZFDLVBOYJCBUAR-HNNXBMFYSA-N 0.000 claims 1
- DTELSNVHSFXARH-INIZCTEOSA-N n-[(1s)-1-[1-[3-[2-(methanesulfonamido)phenyl]phenyl]benzimidazol-5-yl]ethyl]acetamide Chemical compound C1=NC2=CC([C@@H](NC(C)=O)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1NS(C)(=O)=O DTELSNVHSFXARH-INIZCTEOSA-N 0.000 claims 1
- AGKXNDOYPQMADM-UHFFFAOYSA-N n-[1-[1-(3-phenylphenyl)benzimidazol-5-yl]ethyl]acetamide Chemical compound C1=NC2=CC(C(NC(C)=O)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1 AGKXNDOYPQMADM-UHFFFAOYSA-N 0.000 claims 1
- YPKZSIPFSIDDLS-UHFFFAOYSA-N n-[1-[1-(3-phenylphenyl)benzimidazol-5-yl]ethyl]formamide Chemical compound C1=NC2=CC(C(NC=O)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1 YPKZSIPFSIDDLS-UHFFFAOYSA-N 0.000 claims 1
- GSEOCHLBUIMIMP-UHFFFAOYSA-N n-[1-[1-[3-(5-fluoro-2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethyl]acetamide Chemical compound COC1=CC=C(F)C=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)C(C)NC(C)=O)=C1 GSEOCHLBUIMIMP-UHFFFAOYSA-N 0.000 claims 1
- ODJHZYVXKFMQDT-UHFFFAOYSA-N n-[1-[1-[3-(5-fluoro-2-methoxyphenyl)phenyl]benzimidazol-5-yl]ethyl]formamide Chemical compound COC1=CC=C(F)C=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)C(C)NC=O)=C1 ODJHZYVXKFMQDT-UHFFFAOYSA-N 0.000 claims 1
- HPYLJPGWLWPGOI-OAHLLOKOSA-N n-[2-[3-[5-[(1r)-1-aminoethyl]benzimidazol-1-yl]phenyl]phenyl]methanesulfonamide Chemical compound C1=NC2=CC([C@H](N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=C1NS(C)(=O)=O HPYLJPGWLWPGOI-OAHLLOKOSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 208000015238 neurotic disease Diseases 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000020341 sensory perception of pain Effects 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 201000006152 substance dependence Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 0 *c1cccc(C=C)c1 Chemical compound *c1cccc(C=C)c1 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200501719 | 2005-12-05 | ||
| US74253505P | 2005-12-06 | 2005-12-06 | |
| DKPA200601326 | 2006-10-12 | ||
| US85129106P | 2006-10-13 | 2006-10-13 | |
| PCT/EP2006/069237 WO2007065864A1 (en) | 2005-12-05 | 2006-12-04 | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009518292A JP2009518292A (ja) | 2009-05-07 |
| JP2009518292A5 true JP2009518292A5 (enExample) | 2010-01-21 |
Family
ID=37873123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008542778A Abandoned JP2009518292A (ja) | 2005-12-05 | 2006-12-04 | ベンズイミダゾール誘導体及びｇａｂａａ受容体複合体を調節するためのそれらの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7923464B2 (enExample) |
| EP (1) | EP1996556B1 (enExample) |
| JP (1) | JP2009518292A (enExample) |
| KR (1) | KR20080077620A (enExample) |
| AT (1) | ATE449077T1 (enExample) |
| AU (1) | AU2006324046A1 (enExample) |
| CA (1) | CA2632395A1 (enExample) |
| DE (1) | DE602006010602D1 (enExample) |
| DK (1) | DK1996556T3 (enExample) |
| ES (1) | ES2335438T3 (enExample) |
| IL (1) | IL189974A0 (enExample) |
| NO (1) | NO20083045L (enExample) |
| PL (1) | PL1996556T3 (enExample) |
| WO (1) | WO2007065864A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI391381B (zh) | 2006-03-24 | 2013-04-01 | Neurosearch As | 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途 |
| AU2008345696A1 (en) * | 2007-12-21 | 2009-07-09 | Wyeth Llc | Benzimidazole compounds |
| CN102036952A (zh) * | 2008-04-16 | 2011-04-27 | 比奥里波克斯公司 | 用作药物的双芳基化合物 |
| US20110301192A1 (en) * | 2008-10-01 | 2011-12-08 | The Regents Of The University Of California | Inhibitors of Cyclin Kinase Inhibitor p21 |
| WO2010055125A1 (en) * | 2008-11-14 | 2010-05-20 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| WO2010055127A1 (en) * | 2008-11-14 | 2010-05-20 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| RS62761B1 (sr) * | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK40192D0 (da) * | 1992-03-26 | 1992-03-26 | Neurosearch As | Imidazolforbindelser, deres fremstilling og anvendelse |
| CA2218493C (en) | 1995-04-21 | 2005-02-22 | Neurosearch A/S | Benzimidazole compounds and their use as modulators of the gabaa receptor complex |
| AU726447B2 (en) * | 1996-10-21 | 2000-11-09 | Neurosearch A/S | 1-phenyl-benzimidazole compounds and their use as BAGA-A receptor modulators |
| CN1275127A (zh) | 1997-10-10 | 2000-11-29 | 神经研究公司 | 苯并咪唑化合物、含该化合物的药物组合物及其应用 |
| BR0011823A (pt) * | 1999-06-22 | 2002-03-19 | Neurosearch As | Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo |
| AU2002221566A1 (en) | 2000-12-20 | 2002-07-01 | Neurosearch A/S | Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders |
| MXPA05010449A (es) | 2003-04-03 | 2006-05-31 | Neurosearch As | Derivados del bencimidazol y su uso para modular el complejo del receptor de gabaa. |
| US7335777B2 (en) * | 2003-04-03 | 2008-02-26 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the GABAA receptor complex |
| BRPI0413746A (pt) * | 2003-08-21 | 2006-10-24 | Osi Pharm Inc | composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo |
| EP1678144A1 (en) | 2003-10-23 | 2006-07-12 | Akzo Nobel N.V. | 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-a RECEPTOR COMPLEX |
| CA2589770A1 (en) * | 2004-12-01 | 2006-06-08 | Osi Pharmaceuticals, Inc. | N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library |
| CA2604516A1 (en) * | 2005-04-13 | 2006-10-19 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| EP1874758A1 (en) * | 2005-04-19 | 2008-01-09 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| TWI391381B (zh) | 2006-03-24 | 2013-04-01 | Neurosearch As | 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途 |
-
2006
- 2006-12-04 US US12/085,769 patent/US7923464B2/en not_active Expired - Fee Related
- 2006-12-04 DE DE602006010602T patent/DE602006010602D1/de active Active
- 2006-12-04 EP EP06830303A patent/EP1996556B1/en not_active Not-in-force
- 2006-12-04 KR KR1020087013766A patent/KR20080077620A/ko not_active Withdrawn
- 2006-12-04 AT AT06830303T patent/ATE449077T1/de active
- 2006-12-04 CA CA002632395A patent/CA2632395A1/en not_active Abandoned
- 2006-12-04 ES ES06830303T patent/ES2335438T3/es active Active
- 2006-12-04 WO PCT/EP2006/069237 patent/WO2007065864A1/en not_active Ceased
- 2006-12-04 JP JP2008542778A patent/JP2009518292A/ja not_active Abandoned
- 2006-12-04 DK DK06830303.1T patent/DK1996556T3/da active
- 2006-12-04 AU AU2006324046A patent/AU2006324046A1/en not_active Abandoned
- 2006-12-04 PL PL06830303T patent/PL1996556T3/pl unknown
-
2008
- 2008-03-06 IL IL189974A patent/IL189974A0/en unknown
- 2008-07-04 NO NO20083045A patent/NO20083045L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009530353A5 (enExample) | ||
| JPWO2020017587A5 (enExample) | ||
| JP2002523508A5 (enExample) | ||
| JP2005521671A5 (enExample) | ||
| JP2004517852A5 (enExample) | ||
| JP2013537887A5 (enExample) | ||
| RU2008129868A (ru) | Производные бензимидазолов и их применение для модуляции гамка-рецепторного комплекса | |
| JP2005527579A5 (enExample) | ||
| RU2011108281A (ru) | Трипиридилкарбоксамидные антагонисты орексиновых рецепторов | |
| JP2017535559A5 (enExample) | ||
| JP2005518414A5 (enExample) | ||
| RU2014144284A (ru) | Новые агонисты альфа2 адренорецепторов | |
| JP2003507366A5 (enExample) | ||
| AR072876A1 (es) | Derivados de 4,5-dihidro-oxazol-2-ilo , medicamentos que los contienen, metodo de preparacion y uso de los mismos para el tratamiento de enfermedades del sistema nervioso, entre otras. | |
| JP2007500168A5 (enExample) | ||
| RU2011103759A (ru) | Замещенные 6-(1-пиперазинил)-пиридазины в качестве антагонистов 5-нт6 рецептора | |
| JP2007520539A5 (enExample) | ||
| JP2014518212A5 (ja) | 化合物及び組成物 | |
| JP5822079B2 (ja) | 疼痛治療剤 | |
| JP2002525280A5 (enExample) | ||
| JP2009511547A5 (enExample) | ||
| JP2015521643A5 (enExample) | ||
| JP2008542365A5 (enExample) | ||
| WO2006019886A3 (en) | Pyrrolo(oxo)isoquinolines as 5ht ligands | |
| RU2007137096A (ru) | Бензимидазольные производные и их прменение для модуляции рецепторного комплекса гамма-аминомаслянной кислоты (gaba) |